104 PATENT ABSTRACTS A hybrid polypeptide composed of an identification peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that in- cludes segments of DNA coding for the identification peptide and the desired functional protein. The identification peptide consists of a highly antigenic N-terminal portion and a C- terminal linking portion that connects the identification peptide to the N-terminal of the functional protein. The linking portion of the identification peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells trans- formed by the cloning vector is removed there- from and purfied by affinity chromatography techniques by use of an immobilized ligand specific to the antigenic portion of the identification peptide. The protein is then cleaved from the isolated hybrid polypeptide with an appropriate proteolic enzyme or chemical agent, thereby releasing the mature functional protein in highly purified, highly active state. 4783406 METHOD AND COMPOSITIONS FOR USE IN THE TREATMENT OF FIREBLIGHT Peter A Vandenbergh, Anne K Vidaver assigned to Microlife Technics Inc A method and compositions for the treatment of fireblight disease in plants are described. The compositions include a phage for Erwinia amylovora which produces fireblight and an enzyme produced by the phage which depolymerizes a polysaccharide produced by Er- winia amylovora which is the cause of the fireblight disease. Purified enzyme preparations are described. 4783407 GROWTH OF HEPATITUS A VIRUS IN VERO CELLS 4783330 MONOCLONAL ANTIBODIES TO ACTIVATED PLATELETS Bruce Furie, Barbara Furie assigned to New England Medical Center Hospitals lnc An antibody reactive with activated human platelets, and substantially unreactive with resting human platelets, with the azurophilic granules of monocytes, and with granulocytes. Philip J Provost, Paula A Giesa, William McAleer assigned to Merck & Co Inc Hepatitus A virus is grown in Vero cells after passage in in vitro cell culture. Virus replication and continued passage in Vero cells requires ex- tended incubation times, up to about four weeks, for early passages and incubation temperatures no higher than about 32 degrees C. Continued passage results in a significant decrease in incubation time and an increase in virus yield. Cul- tivation of hepatitus A virus in Vero cells meets the development requirements for an inactivated human vaccine. 4783399 DIAGNOSTIC SYSTEM FOR THE DETECTION OF CYTOMEGALOVIRUS 4783411 INFLUENZA-A VIRUS VACCINE FROM FISH CELL CULTURES Michael B Oldstone, George Rice assigned to Scripps Clinic and Research Foundation A mammalian monoclonal receptor is produced by a hybridoma formed by fusion of cells from a myeloma cell line and lymphocytes that produce antibodies that react with a viral antigen from a mammal immunized with cytomegalovirus- infected cells. The monoclonal receptor reacts with the viral antigen in a diagnostic system to detect the presence of cytomegalovirus in a bio- logical sample. JaniGabliks A method for preparing vaccines against influenza-A, and vaccines prepared thereby. Influenza-A virus is subjected to at least two passages in goldfish cell cultures, resulting in at- tenuated virus having reduced infectivity and somewhat altered antigenic characteristics rela- tive to the starting virus, but which when used as a vaccine to innoculate mammalian species con- fers immunity. Immunization tests conducted in mice showed the vaccine to be effective.

4783407 Growth of hepatitus a virus in vero cells

Download PDF Report

Upload
tranminh
View
217
Download
2

Embed Size (px)

Citation preview

Page 1: 4783407 Growth of hepatitus a virus in vero cells

104 PATENT ABSTRACTS

A hybrid polypeptide composed of an identification peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that in- cludes segments of DNA coding for the identification peptide and the desired functional protein. The identification peptide consists of a highly antigenic N-terminal portion and a C- terminal linking portion that connects the identification peptide to the N-terminal of the functional protein. The linking portion of the identification peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells trans- formed by the cloning vector is removed there- from and purfied by affinity chromatography techniques by use of an immobilized ligand specific to the antigenic portion of the identification peptide. The protein is then cleaved from the isolated hybrid polypeptide with an appropriate proteolic enzyme or chemical agent, thereby releasing the mature functional protein in highly purified, highly active state.

4783406

M E T H O D A N D C O M P O S I T I O N S F O R U S E IN T H E T R E A T M E N T

O F F I R E B L I G H T

Peter A Vandenbergh, Anne K Vidaver assigned to Microlife Technics Inc

A method and compositions for the treatment of fireblight disease in plants are described. The compositions include a phage for Erwinia amylovora which produces fireblight and an enzyme produced by the phage which depolymerizes a polysaccharide produced by Er- winia amylovora which is the cause of the fireblight disease. Purified enzyme preparations are described.

4783407

G R O W T H O F H E P A T I T U S A V I R U S IN V E R O C E L L S

4783330

M O N O C L O N A L A N T I B O D I E S T O A C T I V A T E D P L A T E L E T S

Bruce Furie, Barbara Furie assigned to New England Medical Center Hospitals lnc

An antibody reactive with activated human platelets, and substantially unreactive with resting human platelets, with the azurophilic granules of monocytes, and with granulocytes.

Philip J Provost, Paula A Giesa, William McAleer assigned to Merck & Co Inc

Hepatitus A virus is grown in Vero cells after passage in in vitro cell culture. Virus replication and continued passage in Vero cells requires ex- tended incubation times, up to about four weeks, for early passages and incubation temperatures no higher than about 32 degrees C. Continued passage results in a significant decrease in incubation time and an increase in virus yield. Cul- tivation of hepatitus A virus in Vero cells meets the development requirements for an inactivated human vaccine.

4783399

D I A G N O S T I C S Y S T E M F O R T H E D E T E C T I O N O F

C Y T O M E G A L O V I R U S

4783411

I N F L U E N Z A - A V I R U S V A C C I N E F R O M F I S H C E L L C U L T U R E S

Michael B Oldstone, George Rice assigned to Scripps Clinic and Research Foundation

A mammalian monoclonal receptor is produced by a hybridoma formed by fusion of cells from a myeloma cell line and lymphocytes that produce antibodies that react with a viral antigen from a mammal immunized with cytomegalovirus- infected cells. The monoclonal receptor reacts with the viral antigen in a diagnostic system to detect the presence of cytomegalovirus in a bio- logical sample.

JaniGabliks

A method for preparing vaccines against influenza-A, and vaccines prepared thereby. Influenza-A virus is subjected to at least two passages in goldfish cell cultures, resulting in at- tenuated virus having reduced infectivity and somewhat altered antigenic characteristics rela- tive to the starting virus, but which when used as a vaccine to innoculate mammalian species con- fers immunity. Immunization tests conducted in mice showed the vaccine to be effective.